Abstract:Background Epstein Barr virus (EBV) is a highly prevalent herpesvirus worldwide and its infection is associated with malignancies such as nasopharyngeal cancer (NPC), gastric cancer, lymphoepithelioma cancer and lymphoproliferative disorders. Virus-specific T (VST) cell therapies using T cells reactive against EBV have shown limited efficacy in clinical trials with several practical limitations such as the long preparation period and the variations of pre-existing EBV-reactive T cells in different donors. To overcome these technical constraints of the VST approach, we have established the genetically engineered T cells targeting EBV antigens with lentiviral transduction. A proof-of-concept clinical validation was further conducted against EBV+ malignancies (trial No. ChiCTR2100044497). Methods T cells were activated by CD3/CD28 stimulation, lentivirally transduced with codon-optimized CAR (targeting EBV envelope protein) or TCR (targeting EBV latent membrane protein) and further expanded ex vivo. Transgene expression and the T cell phenotype were assessed by flow cytometry. In vitro anti-tumor efficacy was analyzed by IFN-γ ELISA and killing assays such as RTCA Xcelligence. In vivo, the antitumor efficacy of EBV-specific T cells was evaluated in immunocompromised mice bearing human tumor xenografts. Anti-tumor responses in lymphoma and NPC were evaluated by Lugano 2014 and RECIST 1.1 respectively. Results T cells lentivirally transduced with EBV antigen-specific CAR or TCR demonstrated satisfactory surface expression of the introduced receptor and showed increased cytokine production when stimulated to target expressing tumor cells in vitro (figure 1). We have identified the TCRs against EBV latent membrane protein with high functional avidity as determined by peptide dose-response functional assays. In vitro cytotoxicity assays demonstrated strong killing of antigen positive tumor cell lines of the engineered EBV-specific CAR-T or TCR-T cells, while sparing the antigen-negative cells, indicating the specific T cell response. The single intravenous infusion of engineered EBV-specific T cells also led to dose-dependent anti-tumor responses in immunocompromised mouse xenograft models (figure 1). In the clinical trial, two patients with lymphoproliferative disease and one patient with advanced NPC treated with engineered EBV-targeting T cells experienced sustained objective responses. Moreover, in the NPC patient, the EBV DNA copy number decreased from 3.32*103 copies/ml at baseline to normal (<5.00*102 copies/ml) 2 months post infusion. The infused cells also demonstrated satisfactory safety profile with no neurotoxicity and ≥ Grade 2 cytokine release syndrome observed. Conclusions Our data demonstrate the feasibility of using genetically engineered T cells targeting EBV antigens such as envelope protein or latent membrane protein to treat EBV-associated malignancies. Trial Registration Chinese Clinical Trial Registry: ChiCTR2100044497 Ethics Approval All animal studies were conducted at Guangzhou Regenerative Medicine and Health, Guangdong Laboratory as approved by IACUC (2020125). The clinical study was approved by the first affiliated hospital of Zhengzhou University's Ethics Board (L2021-Y027–005).

Evaluation of Epstein-Barr Virus Latent Membrane Protein 2 Specific T-Cell Receptors Driven by T-Cell Specific Promoters Using Lentiviral Vector

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

Anti-nasopharyngeal carcinoma effect in vivo and in vitro of cytotoxicity T lymphocyte induced by Ad5-latent membrane protein 2A]

Induction of EBV Latent Membrane Protein-2A (Lmp2a)-Specific T Cells and Construction of Individualized TCR-engineered T Cells for EBV-associated Malignancies

328 Preclinical Analyses and Proof of Concept Clinical Study of Epstein Barr Virus (EBV) Specific Genetically Modified T Cells Against EBV Associated Malignancies

Induction of the Epstein-Barr Virus Latent Membrane Protein 2 Antigen-specific Cytotoxic T Lymphocytes Using Human Leukocyte Antigen Tetramer-based Artificial Antigen-presenting Cells

The First Functional HLA-a*01:01-Restricted EBV-LMP2-Specific T-Cell Receptors for TCR Gene Therapy of Patients with EBV-Associated Type II/III Malignancies

EBV LMP2A-specific T Cell Immune Responses Elicited by Dendritic Cells Loaded with LMP2A Protein

[Construction and Identification of Recombinant Retroviral Vector and Stable Cell Line Expressing Latent Membrane Protein 2A of Epstein-Barr Virus].

Targeting latent viral infection in EBV-associated lymphomas

Immunogenicity of A Multiepitope Plasmid Dna Encoding T and B Lymphocyte Epitopes from Latent Membrane Protein 2 (lmp2) of Epstein-Barr Virus As A Vaccine in Mice

LMP1-specific cytotoxic T cells for the treatment of EBV-related post-transplantation lymphoproliferative disorders

Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases

Co-targeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma

Nivolumab Treatment of Relapsed/refractory Epstein-Barr Virus–associated Hemophagocytic Lymphohistiocytosis in Adults

[T Cells Recognizing EBV-epitopes Arose in Co-Culture of Peripheral Blood Mononuclear Cells from EB-infected Patients and Dendritic Cells Loaded with LMP2-mixed Peptides].

Prokaryotic Expression and Antigen Characteristics of EB Virus Latent Membrane Protein 2 ( EBV-LMP2) Multi-Epitopes

mRNA‐based Vaccines Targeting the T‐cell Epitope‐rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti‐Tumor Immunity in Mice

T Cells Expressing a LMP1-specific Chimeric Antigen Receptor Mediate Antitumor Effects Against LMP1-positive Nasopharyngeal Carcinoma Cells in Vitro and in Vivo.

[Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].

TianTan vaccinia virus-based EBV vaccines targeting both latent and lytic antigens elicits potent immunity against lethal EBV challenge in humanized mice